MCID: NRB001
MIFTS: 72

Neuroblastoma

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Neuroblastoma

MalaCards integrated aliases for Neuroblastoma:

Name: Neuroblastoma 57 12 76 53 25 59 37 29 13 6 43 44 15 40 73
Neuroblastoma 1 57 75 29 6
Nb 53 25
Neuroblastoma, Susceptibility to, Type 1 40
Neuroblastoma, Susceptibility to, 1 57
Neuroblastoma, Susceptibility to 57
Central Neuroblastoma 73
Nblst1 75

Characteristics:

Orphanet epidemiological data:

59
neuroblastoma
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Childhood; Age of death: adolescent,late childhood;

OMIM:

57
Inheritance:
autosomal dominant
isolated cases

Miscellaneous:
genetic heterogeneity
incomplete penetrance
mean age of onset 14-24 months
highly variable clinical phenotype
symptoms vary according to location of tumor
spontaneous tumor regression may occur
usually sporadic, but 1-2% of cases are familial
n-myc oncogene amplification is associated with poor prognosis


HPO:

32
neuroblastoma:
Onset and clinical course incomplete penetrance
Inheritance heterogeneous autosomal dominant inheritance sporadic


Classifications:

Orphanet: 59  
Rare neurological diseases


Summaries for Neuroblastoma

OMIM : 57 Neuroblastoma is the most common childhood cancer diagnosed before the age of 1 year, and accounts for 10 to 15% of all cancer deaths in children. Some patients inherit a genetic predisposition to neuroblastoma due to germline mutations, whereas others develop sporadic disease that may result from either germline or somatic mutations. Neuroblastoma tumors are derived from embryonic cells that form the primitive neural crest and give rise to the adrenal medulla and the sympathetic nervous system (Roberts et al., 1998; Eng, 2008). Histopathologically, neuroblastoma can range in type from the most aggressive form, neuroblastoma, composed entirely of immature neural precursor cells, to ganglioneuroma, composed entirely of mature neural tissue. The most important prognostic factor for patients with neuroblastoma is the extent of the tumor at the time of diagnosis (Roberts et al., 1998). Neuroblastoma can also be part of cancer-prone syndromes, such as paragangliomas (see, e.g., PGL4; 115310). (256700)

MalaCards based summary : Neuroblastoma, also known as neuroblastoma 1, is related to medulloblastoma and rhabdomyosarcoma, and has symptoms including back pain, headache and pain. An important gene associated with Neuroblastoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways is Transcriptional misregulation in cancer. The drugs Unituxin and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, bone and bone marrow, and related phenotypes are neoplasm of the nervous system and elevated urinary catecholamines

UniProtKB/Swiss-Prot : 75 Neuroblastoma 1: A common neoplasm of early childhood arising from embryonic cells that form the primitive neural crest and give rise to the adrenal medulla and the sympathetic nervous system.

NIH Rare Diseases : 53 Neuroblastoma is a tumor that develops from a nerve in a child, usually before the age of 5.  It occurs in the abdomen near the adrenal glands, but it can also occur in other parts of the body.  It is considered an aggressive tumor because it often spreads to other parts of the body (metastasizes).  The symptoms of a neuroblastoma may include a lump in the abdomen, pain, diarrhea, or generally feeling unwell.  It affects one out of 100,000 children.  The exact cause of this tumor is not yet known.  Neuroblastoma may be diagnosed by physical examination; specific blood tests; imaging tests such as x-rays, magnetic resonance imaging (MRI), or computed tomography (CT) scans; and a biopsy.  Treatment depends on the size and location of the tumor within the body, as well as the child’s age. Surgery is often the first step of treatment, and may be followed by chemotherapy, radiation therapy, or a stem cell transplant in more severe cases.

MedlinePlus : 43 Neuroblastoma is a cancer that forms in your nerve tissue. It usually begins in the adrenal glands, which sit atop your kidneys. It may also begin in your neck, chest or spinal cord. The cancer often begins in early childhood. Sometimes it begins before a child is born. By the time doctors find the cancer, it has usually spread to other parts of the body. The most common symptoms are A lump in the abdomen, neck or chest Bulging eyes Dark circles around the eyes Bone pain Swollen stomach and trouble breathing in babies Painless, bluish lumps under the skin in babies Inability to move a body part Treatments include surgery, radiation therapy, chemotherapy, biologic therapy, or a combination. Biologic therapy boosts your body's own ability to fight cancer. Sometimes before giving treatment, doctors wait to see whether symptoms get worse. This is called watchful waiting. NIH: National Cancer Institute

Genetics Home Reference : 25 Neuroblastoma is a type of cancer that most often affects children. Neuroblastoma occurs when immature nerve cells called neuroblasts become abnormal and multiply uncontrollably to form a tumor. Most commonly, the tumor originates in the nerve tissue of the adrenal gland located above each kidney. Other common sites for tumors to form include the nerve tissue in the abdomen, chest, neck, or pelvis. Neuroblastoma can spread (metastasize) to other parts of the body such as the bones, liver, or skin.

Disease Ontology : 12 An autonomic nervous system neoplasm that derives from immature nerve cells.

Wikipedia : 76 Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently... more...

Related Diseases for Neuroblastoma

Diseases in the Neuroblastoma family:

Neuroblastoma 2 Neuroblastoma 3
Neuroblastoma 4 Neuroblastoma 5
Neuroblastoma 6 Neuroblastoma 7

Diseases related to Neuroblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 374)
# Related Disease Score Top Affiliating Genes
1 medulloblastoma 33.5 FGFR1 H19 MIR34A MYCNOS TP53
2 rhabdomyosarcoma 32.0 ALK H19 PTPN11 TP53
3 astrocytoma 31.7 FGFR1 H19 PTPN11 SNHG1
4 adenocarcinoma 31.4 ALK FGFR1 H19 TP53
5 glioma 31.4 FGFR1 GAS5 H19 HAGLR MALAT1 MIR184
6 glioblastoma 31.3 ALK FGFR1 GAS5 H19 MALAT1 MIR34A
7 melanoma 30.9 CASC15 GAS5 H19 MALAT1 MIR184 MIR34A
8 breast cancer 30.8 ALK FGFR1 GAS5 H19 MALAT1 MIR34A
9 lung cancer 30.6 ALK FGFR1 GAS5 H19 HAGLR MALAT1
10 adrenocortical carcinoma, hereditary 30.6 H19 MIR184 TP53
11 myeloma, multiple 30.6 GAS5 H19 MALAT1 PTPN11 TP53
12 ovarian cancer 30.3 GAS5 H19 HAGLR MALAT1 NBAT1 NME1
13 thyroid cancer, nonmedullary, 1 30.0 GAS5 H19 HAGLR MALAT1 MIR34A
14 colorectal cancer 30.0 GAS5 H19 MALAT1 MIR34A NME1 PTPN11
15 prostate cancer 29.7 FGFR1 GAS5 H19 MALAT1 MIR184 MIR34A
16 olfactory neuroblastoma 12.3
17 neuroblastoma 2 12.3
18 neuroblastoma 3 12.3
19 cervical neuroblastoma 12.2
20 cerebral neuroblastoma 12.1
21 adrenal neuroblastoma 12.1
22 nijmegen breakage syndrome 12.1
23 differentiating neuroblastoma 12.0
24 extracranial neuroblastoma 12.0
25 retroperitoneal neuroblastoma 12.0
26 renal cell carcinoma associated with neuroblastoma 12.0
27 neuroblastoma 4 11.9
28 neuroblastoma 5 11.9
29 neuroblastoma 6 11.9
30 nasal cavity olfactory neuroblastoma 11.9
31 spinal cord neuroblastoma 11.9
32 neuroblastoma 7 11.8
33 mediastinum neuroblastoma 11.8
34 nicolaides-baraitser syndrome 11.7
35 retinoblastoma 11.6
36 autonomic nervous system neoplasm 11.5 ALK MYCNOS TP53
37 parameningeal embryonal rhabdomyosarcoma 11.5 ALK TP53
38 peripheral t-cell lymphoma 11.5 ALK NME1 TP53
39 hematologic cancer 11.5 ALK FGFR1 PTPN11 TP53
40 lung squamous cell carcinoma 11.4 ALK FGFR1 PTPN11 SNHG1 TP53
41 lung papillary adenocarcinoma 11.3 ALK TP53
42 opsoclonus-myoclonus syndrome 11.3
43 central hypoventilation syndrome, congenital 11.3
44 pilocytic astrocytoma 11.3 FGFR1 PTPN11 TP53
45 respiratory system cancer 11.3 ALK MALAT1 TP53
46 ganglioneuroblastoma 11.2
47 myeloproliferative neoplasm 11.2 FGFR1 H19 PTPN11
48 gastric adenocarcinoma 11.2 FGFR1 H19 NME1 TP53
49 weaver syndrome 11.2
50 myoclonic encephalopathy of infants 11.2

Graphical network of the top 20 diseases related to Neuroblastoma:



Diseases related to Neuroblastoma

Symptoms & Phenotypes for Neuroblastoma

Symptoms via clinical synopsis from OMIM:

57
Neurologic Central Nervous System:
ataxia
myoclonus
opsoclonus
spinal cord compression
paraneoplastic syndromes

Metabolic Features:
fever

Neoplasia:
ganglioneuroma
ganglioneuroblastoma
neuroblastoma, arises anywhere along the sympathetic chain (including intracranially)
adrenal glands are most common site

Head And Neck Eyes:
horner's syndrome
periorbital ecchymoses (soft tissue involvement)

Chest:
mediastinal mass with calcifications on radiology

Skeletal:
bone pain (with metastatic disease)

Hematology:
anemia (with bone marrow involvement)

Growth Other:
failure to thrive

Abdomen:
abdominal pain
palpable abdominal mass
abdominal mass with calcifications on radiology

Growth Weight:
weight loss (with disseminated disease)

Cardiovascular Vascular:
hypertension (compression of renal arteries)

Abdomen Gastrointestinal:
diarrhea (due to vasoactive intestinal peptide)

Skin Nails Hair Skin:
bluish skin nodules

Laboratory Abnormalities:
increased urinary catecholamines
increased urinary homovanillic acid (hva)
increased urinary vanillylmandelic acid (vma)
increased urinary dopamine
tumor may secrete vasoactive intestinal peptide (vip)


Clinical features from OMIM:

256700

Human phenotypes related to Neuroblastoma:

59 32 (show all 23)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neoplasm of the nervous system 59 32 hallmark (90%) Very frequent (99-80%) HP:0004375
2 elevated urinary catecholamines 59 32 hallmark (90%) Very frequent (99-80%) HP:0011976
3 hypertension 32 HP:0000822
4 ataxia 32 HP:0001251
5 failure to thrive 32 HP:0001508
6 fever 32 HP:0001945
7 anemia 32 HP:0001903
8 abdominal pain 32 HP:0002027
9 weight loss 32 HP:0001824
10 abnormality of the thorax 32 HP:0000765
11 myoclonus 32 HP:0001336
12 diarrhea 32 HP:0002014
13 bone pain 32 HP:0002653
14 neuroblastoma 32 HP:0003006
15 skin nodule 32 HP:0200036
16 ganglioneuroma 32 HP:0003005
17 horner syndrome 32 HP:0002277
18 ganglioneuroblastoma 32 HP:0006747
19 opsoclonus 32 HP:0010543
20 spinal cord compression 32 HP:0002176
21 elevated urinary dopamine 32 HP:0011979
22 elevated urinary homovanillic acid 32 HP:0011977
23 elevated urinary vanillylmandelic acid 32 HP:0011978

UMLS symptoms related to Neuroblastoma:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, sleeplessness

Drugs & Therapeutics for Neuroblastoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Unituxin 18 49 DINUTUXIMAB United Therapeutics March 2015

Drugs for Neuroblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 406)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 22916-47-8 4189
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
3
Itraconazole Approved, Investigational Phase 4,Phase 3,Not Applicable 84625-61-6 55283
4
Nicotine Approved Phase 4 54-11-5 942 89594
5 Antifungal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
6 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16
Hydroxyitraconazole Phase 4,Phase 3,Not Applicable
17 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2,Not Applicable
19
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
20
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
21
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
22
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
23
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
24
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
25
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
26
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 148-82-3 4053 460612
27
Isotretinoin Approved Phase 3,Phase 1,Phase 2,Not Applicable 4759-48-2 5538 5282379
28
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
29
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
30
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 119413-54-6, 123948-87-8 60700
31
Vindesine Approved, Investigational Phase 3,Phase 2,Not Applicable 59917-39-4, 53643-48-4 40839
32
Aldesleukin Approved Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
33
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 52-24-4 5453
34
rituximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
35
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
36
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598
37
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
38
Captopril Approved Phase 3 62571-86-2 44093
39
Palivizumab Approved, Investigational Phase 3 188039-54-5
40
Ribavirin Approved Phase 3 36791-04-5 37542
41
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
42
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
43
Caspofungin Approved Phase 3,Phase 2,Not Applicable 179463-17-3, 162808-62-0 468682 2826718
44
Acyclovir Approved Phase 3 59277-89-3 2022
45
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7553-56-2 807
46
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
47
Crizotinib Approved Phase 3,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
48
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
49
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
50 Estradiol valerate Approved, Investigational, Vet_approved Phase 3 979-32-8

Interventional clinical trials:

(show top 50) (show all 557)
# Name Status NCT ID Phase Drugs
1 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
2 Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4 Panitumumab
3 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
4 Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma Unknown status NCT00276731 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;vincristine sulfate
5 Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma Unknown status NCT00416676 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;vincristine sulfate
6 Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant Unknown status NCT00417053 Phase 3 busulfan;carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide phosphate;melphalan;vincristine sulfate
7 Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma Unknown status NCT00030719 Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;isotretinoin;melphalan;vincristine sulfate
8 Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma Unknown status NCT00410631 Phase 3 carboplatin;cisplatin;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide phosphate;ifosfamide;isotretinoin;melphalan;topotecan hydrochloride;vincristine sulfate;vindesine
9 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
10 Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients Completed NCT03042429 Phase 3 Cycles N8, N5 and N6;Cycles N5 and N6
11 Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma Completed NCT00499616 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;topotecan hydrochloride;Isotretinoin;Filgrastim
12 Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma Completed NCT00365755 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;melphalan;vincristine sulfate
13 Surgery in Treating Children With Neuroblastoma Completed NCT00003119 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
14 Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma Completed NCT00025428 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
15 Combination Chemotherapy in Treating Children With Neuroblastoma Completed NCT00003093 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
16 Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma Completed NCT00002802 Phase 3 carboplatin;cisplatin;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;mesna;vincristine sulfate;vindesine
17 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma Completed NCT00004188 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;isotretinoin;melphalan;topotecan hydrochloride;vincristine sulfate
18 Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed NCT00126412 Phase 3 123I-mIBG (meta-iodobenzylguanidine)
19 Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma Completed NCT00033293 Phase 3 cyclophosphamide;prednisone;Corticotropin-Releasing Hormone
20 Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma Completed NCT01041638 Phase 3 Isotretinoin
21 Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Completed NCT00026312 Phase 3 Isotretinoin
22 Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma Completed NCT00567567 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Isotretinoin;Melphalan;Thiotepa;Topotecan Hydrochloride;Vincristine Sulfate Liposome
23 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
24 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
25 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
26 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
27 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
28 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
29 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
30 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
31 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
32 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
33 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
34 Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer Completed NCT01412957 Phase 3 Panitumumab
35 Naxitamab for Neuroblastoma With Osteomedullary Disease Recruiting NCT03363373 Phase 3
36 European Low and Intermediate Risk Neuroblastoma Protocol Recruiting NCT01728155 Phase 3 chemotherapy
37 High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) Recruiting NCT01704716 Phase 3 Vincristine;Aldesleukin;ch14.18/CHO;Carboplatin;Etoposide;Cisplatin;Cyclophosphamide;Doxorubicin;G-CSF;Busulfan;Melphalan
38 Testing the Addition of 131I-MIBG or Crizotinib to Intensive Therapy in People With High-risk Neuroblastoma (NBL) Recruiting NCT03126916 Phase 3 Busulfan;Carboplatin;Cisplatin;Crizotinib;Cyclophosphamide;Dexrazoxane Hydrochloride;Doxorubicin Hydrochloride;Etoposide Phosphate;Isotretinoin;Melphalan;Thiotepa;Topotecan Hydrochloride;Vincristine Sulfate
39 Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma Recruiting NCT02176967 Phase 3 Carboplatin;Etoposide;Cyclophosphamide;Doxorubicin Hydrochloride
40 Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) Recruiting NCT01868269 Phase 3 Dexamethasone acetate;dexamethasone and cyclophosphamide;dexamethasone and rituximab
41 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Recruiting NCT03042416 Phase 3 18F-DOPA
42 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Active, not recruiting NCT00554788 Phase 3 cisplatin;cyclophosphamide;etoposide;carboplatin;vincristine sulfate;thiotepa
43 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
44 131I-burtomab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases Not yet recruiting NCT03275402 Phase 2, Phase 3
45 Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma Terminated NCT00539500 Phase 2, Phase 3 Carboplatin;Etoposide;Melphalan
46 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
47 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
48 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
49 Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma Unknown status NCT01156350 Phase 2 Busulfan - Fludarabine - TBI
50 Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma Unknown status NCT00392340 Phase 2 doxorubicin hydrochloride;topotecan hydrochloride;vincristine sulfate

Search NIH Clinical Center for Neuroblastoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: neuroblastoma

Genetic Tests for Neuroblastoma

Genetic tests related to Neuroblastoma:

# Genetic test Affiliating Genes
1 Neuroblastoma 29 KIF1B NME1
2 Neuroblastoma 1 29

Anatomical Context for Neuroblastoma

MalaCards organs/tissues related to Neuroblastoma:

41
Adrenal Gland, Bone, Bone Marrow, Brain, Skin, T Cells, Testes

Publications for Neuroblastoma

Articles related to Neuroblastoma:

(show top 50) (show all 5117)
# Title Authors Year
1
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. ( 29967609 )
2018
2
Origin and initiation mechanisms of neuroblastoma. ( 29445860 )
2018
3
Neuroprotective effects of seaweeds against 6-hydroxidopamine-induced cell death on an in vitro human neuroblastoma model. ( 29444677 )
2018
4
TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma. ( 28452859 )
2018
5
DNA methylation-based reclassification of olfactory neuroblastoma. ( 29730775 )
2018
6
P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB). ( 29959561 )
2018
7
Real-time determination of aggregated alpha-synuclein induced membrane disruption at neuroblastoma cells using scanning ion conductance microscopy. ( 29974096 )
2018
8
Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-I_B activation. ( 29423589 )
2018
9
Quantification of total dinutuximab concentrations in neuroblastoma patients with liquid chromatography tandem mass spectrometry. ( 29938370 )
2018
10
Effects of Cordyceps sinensis on macrophage function in high-fat diet fed rats and its anti-proliferative effects on IMR-32 human neuroblastoma cells. ( 29348077 )
2018
11
Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma. ( 29977157 )
2018
12
Surgical Treatment of Olfactory Neuroblastoma: Major Complication Rates, Progression Free and Overall Survival. ( 29868319 )
2018
13
Mutations in the Neuroblastoma Amplified Sequence gene in a family affected by Acrofrontofacionasal Dysostosis type 1. ( 29929043 )
2018
14
Vandetanib inhibits cisplatina89resistant neuroblastoma tumor growth and invasion. ( 29436676 )
2018
15
Olfactory Neuroblastoma. ( 29411144 )
2018
16
Activation of transglutaminase 2 by nerve growth factor in differentiating neuroblastoma cells: A role in cell survival and neurite outgrowth. ( 29242118 )
2018
17
microRNA-494 Favors HO-1 Expression in Neuroblastoma Cells Exposed to Oxidative Stress in a Bach1-Independent Way. ( 29951371 )
2018
18
The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines. ( 29947893 )
2018
19
Yap-Hippo pathway regulates cerebral hypoxia-reoxygenation injury in neuroblastoma N2a cells via inhibiting ROCK1/F-actin/mitochondrial fission pathways. ( 29796942 )
2018
20
Guidelines on nuclear medicine imaging in neuroblastoma. ( 29938300 )
2018
21
ZNF281 inhibits neuronal differentiation and is a prognostic marker for neuroblastoma. ( 29941555 )
2018
22
Scavenger receptor class B type 1 regulates neuroblastoma cell proliferation, migration and invasion. ( 29128352 )
2018
23
S-trityl-L-cysteine, a novel Eg5 inhibitor, is a potent chemotherapeutic strategy in neuroblastoma. ( 29963178 )
2018
24
Sinonasal Neuroendocrine Neoplasms: Current Challenges and Advances in Diagnosis and Treatment, with a Focus on Olfactory Neuroblastoma. ( 29427030 )
2018
25
Silencing of NADPH oxidase 4 attenuates hypoxia resistance in neuroblastoma cells SHSY-5Y by inhibiting PI3K/Akt-dependent glycolysis. ( 29426376 )
2018
26
Age distribution and age-related outcomes of olfactory neuroblastoma: a population-based analysis. ( 29881306 )
2018
27
Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance. ( 29968769 )
2018
28
MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. ( 29445162 )
2018
29
Burkholderia Lethal Factor 1, a Novel Anti-Cancer Toxin, Demonstrates Selective Cytotoxicity in MYCN-Amplified Neuroblastoma Cells. ( 29954071 )
2018
30
Survival outcome of intermediate risk neuroblastoma at Children Cancer Hospital Egypt. ( 29428371 )
2018
31
Triptolide inhibits proliferation and migration of human neuroblastoma SH-SY5Y cells by up-regulating microRNA-181a. ( 29426375 )
2018
32
Ectopic Cushing's syndrome secondary to olfactory neuroblastoma. ( 29340776 )
2018
33
Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved? ( 29439882 )
2018
34
A physiologically relevant 3D collagen-based scaffold - neuroblastoma cell system exhibits chemosensitivity similar to orthotopic xenograft models. ( 29447961 )
2018
35
Rare MYC-amplified Neuroblastoma With Large Cell Histology. ( 29426276 )
2018
36
PHF20 collaborates with PARP1 to promote stemness and aggressiveness of neuroblastoma cells through activation of SOX2 and OCT4. ( 29452418 )
2018
37
PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma. ( 29440296 )
2018
38
Neuroprotective Effects of Phenolic and Carboxylic Acids on Oxidative Stress-Induced Toxicity in Human Neuroblastoma SH-SY5Y Cells. ( 29417471 )
2018
39
A case of neuroblastoma in DICER1 syndrome: Chance finding or noncanonical causation? ( 28766837 )
2018
40
Induction of cross-tolerance between protective effect of morphine and nicotine in 6-hydroxydopamine-induce neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells. ( 29947270 )
2018
41
Paraneoplastic limbic encephalitis associated with mixed olfactory neuroblastoma and craniopharyngioma: A case report and literature review. ( 29901583 )
2018
42
In situ monitoring of PTHLH secretion in neuroblastoma cells cultured onto nanoporous membranes. ( 29438908 )
2018
43
Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. ( 29939160 )
2018
44
Methamphetamine toxicity-induced calcineurin activation, nuclear translocation of nuclear factor of activated T-cells and elevation of cyclooxygenase 2 levels are averted by calpastatin overexpression in neuroblastoma SH-SY5Y cells. ( 29944913 )
2018
45
Predictive Modeling of Neuroblastoma Growth Dynamics in Xenograft Model After Bevacizumab Anti-VEGF Therapy. ( 29948886 )
2018
46
Incidental neuroblastoma with bilateral retinoblastoma: what are the chances? ( 29336617 )
2018
47
Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib. ( 29948946 )
2018
48
Different inhibitory effects on the proliferation and apoptosis of human and laboratory Borna disease virusa89infected human neuroblastoma SHa89SY5Y cells inA vitro. ( 29115502 )
2018
49
<i>MYCN</i> Amplification Promotes Enhancer Invasion in Neuroblastoma. ( 29439151 )
2018
50
An unusual manifestation of olfactory neuroblastoma. ( 29535093 )
2018

Variations for Neuroblastoma

ClinVar genetic disease variations for Neuroblastoma:

6
(show top 50) (show all 493)
# Gene Variation Type Significance SNP ID Assembly Location
1 KIF1B NM_015074.3(KIF1B): c.1937A> T (p.Glu646Val) single nucleotide variant risk factor rs121908161 GRCh37 Chromosome 1, 10357264: 10357264
2 KIF1B NM_015074.3(KIF1B): c.1937A> T (p.Glu646Val) single nucleotide variant risk factor rs121908161 GRCh38 Chromosome 1, 10297206: 10297206
3 KIF1B NM_015074.3(KIF1B): c.3649C> T (p.Pro1217Ser) single nucleotide variant Likely pathogenic rs121908163 GRCh37 Chromosome 1, 10406001: 10406001
4 KIF1B NM_015074.3(KIF1B): c.3649C> T (p.Pro1217Ser) single nucleotide variant Likely pathogenic rs121908163 GRCh38 Chromosome 1, 10345943: 10345943
5 KIF1B NM_015074.3(KIF1B): c.4442G> A (p.Ser1481Asn) single nucleotide variant Pathogenic,risk factor rs121908164 GRCh37 Chromosome 1, 10425534: 10425534
6 KIF1B NM_015074.3(KIF1B): c.4442G> A (p.Ser1481Asn) single nucleotide variant Pathogenic,risk factor rs121908164 GRCh38 Chromosome 1, 10365476: 10365476
7 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
8 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh38 Chromosome 12, 112450406: 112450406
9 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
10 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
11 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
12 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
13 ALK NM_004304.4(ALK): c.3824G> A (p.Arg1275Gln) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994087 GRCh37 Chromosome 2, 29432664: 29432664
14 ALK NM_004304.4(ALK): c.3824G> A (p.Arg1275Gln) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994087 GRCh38 Chromosome 2, 29209798: 29209798
15 ALK NM_004304.4(ALK): c.3383G> C (p.Gly1128Ala) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994088 GRCh37 Chromosome 2, 29445450: 29445450
16 ALK NM_004304.4(ALK): c.3383G> C (p.Gly1128Ala) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994088 GRCh38 Chromosome 2, 29222584: 29222584
17 ALK NM_004304.4(ALK): c.3575G> C (p.Arg1192Pro) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994089 GRCh37 Chromosome 2, 29443642: 29443642
18 ALK NM_004304.4(ALK): c.3575G> C (p.Arg1192Pro) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994089 GRCh38 Chromosome 2, 29220776: 29220776
19 ALK NM_004304.4(ALK): c.3452C> T (p.Thr1151Met) single nucleotide variant Pathogenic,risk factor rs113994091 GRCh37 Chromosome 2, 29445273: 29445273
20 ALK NM_004304.4(ALK): c.3452C> T (p.Thr1151Met) single nucleotide variant Pathogenic,risk factor rs113994091 GRCh38 Chromosome 2, 29222407: 29222407
21 ALK NM_004304.4(ALK): c.3749T> C (p.Ile1250Thr) single nucleotide variant Pathogenic/Likely pathogenic rs113994092 GRCh37 Chromosome 2, 29432739: 29432739
22 ALK NM_004304.4(ALK): c.3749T> C (p.Ile1250Thr) single nucleotide variant Pathogenic/Likely pathogenic rs113994092 GRCh38 Chromosome 2, 29209873: 29209873
23 ALK NM_004304.4(ALK): c.3520T> G (p.Phe1174Val) single nucleotide variant Pathogenic rs281864719 GRCh37 Chromosome 2, 29443697: 29443697
24 ALK NM_004304.4(ALK): c.3520T> G (p.Phe1174Val) single nucleotide variant Pathogenic rs281864719 GRCh38 Chromosome 2, 29220831: 29220831
25 ALK NM_004304.4(ALK): c.3733T> G (p.Phe1245Val) single nucleotide variant Pathogenic rs281864720 GRCh37 Chromosome 2, 29436860: 29436860
26 ALK NM_004304.4(ALK): c.3733T> G (p.Phe1245Val) single nucleotide variant Pathogenic rs281864720 GRCh38 Chromosome 2, 29213994: 29213994
27 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
28 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs121913254 GRCh38 Chromosome 1, 114713909: 114713909
29 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs121913254 NCBI36 Chromosome 1, 115058053: 115058053
30 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
31 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
32 KIF1B NM_015074.3(KIF1B): c.1639+10C> T single nucleotide variant Benign rs3753037 GRCh37 Chromosome 1, 10355834: 10355834
33 KIF1B NM_015074.3(KIF1B): c.1639+10C> T single nucleotide variant Benign rs3753037 GRCh38 Chromosome 1, 10295776: 10295776
34 PHOX2B NM_003924.3(PHOX2B): c.870C> A (p.Pro290=) single nucleotide variant Benign rs17885864 GRCh37 Chromosome 4, 41747899: 41747899
35 PHOX2B NM_003924.3(PHOX2B): c.870C> A (p.Pro290=) single nucleotide variant Benign rs17885864 GRCh38 Chromosome 4, 41745882: 41745882
36 PTPN11 NM_002834.4(PTPN11): c.214G> A (p.Ala72Thr) single nucleotide variant Likely pathogenic rs121918453 GRCh37 Chromosome 12, 112888198: 112888198
37 PTPN11 NM_002834.4(PTPN11): c.214G> A (p.Ala72Thr) single nucleotide variant Likely pathogenic rs121918453 GRCh38 Chromosome 12, 112450394: 112450394
38 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
39 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
40 KIF1B NM_015074.3(KIF1B): c.3507G> A (p.Pro1169=) single nucleotide variant Benign/Likely benign rs147318592 GRCh37 Chromosome 1, 10403302: 10403302
41 KIF1B NM_015074.3(KIF1B): c.3507G> A (p.Pro1169=) single nucleotide variant Benign/Likely benign rs147318592 GRCh38 Chromosome 1, 10343244: 10343244
42 KIF1B NM_015074.3(KIF1B): c.2455A> C (p.Ser819Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs140015591 GRCh37 Chromosome 1, 10384871: 10384871
43 KIF1B NM_015074.3(KIF1B): c.2455A> C (p.Ser819Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs140015591 GRCh38 Chromosome 1, 10324813: 10324813
44 KIF1B NM_015074.3(KIF1B): c.2466C> T (p.Asp822=) single nucleotide variant Conflicting interpretations of pathogenicity rs145846362 GRCh37 Chromosome 1, 10384882: 10384882
45 KIF1B NM_015074.3(KIF1B): c.2466C> T (p.Asp822=) single nucleotide variant Conflicting interpretations of pathogenicity rs145846362 GRCh38 Chromosome 1, 10324824: 10324824
46 KIF1B NM_015074.3(KIF1B): c.4458C> T (p.Pro1486=) single nucleotide variant Conflicting interpretations of pathogenicity rs147066476 GRCh37 Chromosome 1, 10425550: 10425550
47 KIF1B NM_015074.3(KIF1B): c.4458C> T (p.Pro1486=) single nucleotide variant Conflicting interpretations of pathogenicity rs147066476 GRCh38 Chromosome 1, 10365492: 10365492
48 ALK NM_004304.4(ALK): c.3833A> C (p.Tyr1278Ser) single nucleotide variant Pathogenic rs863225285 GRCh38 Chromosome 2, 29209789: 29209789
49 ALK NM_004304.4(ALK): c.3833A> C (p.Tyr1278Ser) single nucleotide variant Pathogenic rs863225285 GRCh37 Chromosome 2, 29432655: 29432655
50 ALK NM_004304.4(ALK): c.3734T> G (p.Phe1245Cys) single nucleotide variant Pathogenic rs863225283 GRCh38 Chromosome 2, 29213993: 29213993

Copy number variations for Neuroblastoma from CNVD:

7 (show top 50) (show all 232)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13319 1 1 124300000 Amplification and lo ss Neuroblastoma
2 13325 1 1 124300000 Deletion Neuroblastoma
3 13344 1 1 125000000 Copy number Neuroblastoma
4 13349 1 1 125000000 Deletion Neuroblastoma
5 13355 1 1 125000000 Loss Neuroblastoma
6 13407 1 1 2300000 Copy number GNB1 Neuroblastoma
7 13408 1 1 2300000 Copy number SLC35E2 Neuroblastoma
8 13751 1 1 27800000 Loss Neuroblastoma
9 13762 1 1 28000000 Deletion Neuroblastoma
10 13837 1 10001852 10151200 Loss KIF1B Neuroblastoma
11 16476 1 125000000 249250621 Copy number CHD5 Neuroblastoma
12 16477 1 125000000 249250621 Copy number KIF1B Neuroblastoma
13 16597 1 128000000 247249719 Gain Neuroblastoma
14 16598 1 128000000 247249719 Gain Neuroblastoma
15 17283 1 142400000 148000000 Copy number NBPF23 Neuroblastoma
16 17374 1 142600000 147000000 Copy number NBPF1 Neuroblastoma
17 17375 1 142600000 147000000 Copy number NBPF15 Neuroblastoma
18 17376 1 142600000 147000000 Copy number NBPF3 Neuroblastoma
19 18773 1 147305744 147427061 Copy number NBPF Neuroblastoma
20 20614 1 153300000 247249719 Gain Neuroblastoma
21 20884 1 155000000 249250621 Gain Neuroblastoma
22 26022 1 195715155 196905060 Gain Neuroblastoma
23 27292 1 206429564 209469901 Gain Neuroblastoma
24 29290 1 2300000 12600000 Loss Neuroblastoma
25 29291 1 2300000 12600000 Loss Neuroblastoma
26 29292 1 2300000 12700000 Loss Neuroblastoma
27 32651 1 3815958 4146056 Amplification DFFB Neuroblastoma
28 32934 1 4056522 10472147 Loss Neuroblastoma
29 33588 1 46500000 51300000 Deletion Neuroblastoma
30 34972 1 5871399 5949729 Loss CHD5 Neuroblastoma
31 36107 1 7200000 16200000 Copy number Neuroblastoma
32 37032 1 84700000 88100000 Deletion Neuroblastoma
33 42798 10 40200000 135534747 Loss Neuroblastoma
34 43291 10 46100000 50100000 Gain Neuroblastoma
35 48305 11 1 10700000 Loss Neuroblastoma
36 48306 11 1 10700000 Loss Neuroblastoma
37 48334 11 1 2800000 Gain Neuroblastoma
38 49040 11 102400000 134452384 Deletion Neuroblastoma
39 49300 11 10515175 10701970 Amplification MRVI1 Neuroblastoma
40 49301 11 10515175 10701970 Amplification RNF141 Neuroblastoma
41 49302 11 10515175 10701970 Amplification XLKD1 Neuroblastoma
42 49698 11 110314720 118319416 Loss Neuroblastoma
43 50154 11 114581997 114912893 Loss CADM1 Neuroblastoma
44 51496 11 12700000 16200000 Copy number SOX6 Neuroblastoma
45 52328 11 16100000 21600000 Deletion Neuroblastoma
46 52785 11 19817525 19848438 Amplification NAV2 Neuroblastoma
47 52827 11 2043796 2201921 Amplification IGF2 Neuroblastoma
48 52828 11 2043796 2201921 Amplification INS Neuroblastoma
49 52829 11 2043796 2201921 Amplification TH Neuroblastoma
50 53355 11 2800000 10700000 Duplication LMO1 Neuroblastoma

Expression for Neuroblastoma

LifeMap Discovery
Genes differentially expressed in tissues of Neuroblastoma patients vs. healthy controls: 35 (show top 50) (show all 640)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 STAR steroidogenic acute regulatory protein Adrenal Gland - 9.57 0.000
2 CYP11A1 cytochrome P450, family 11, subfamily A, polypeptide 1 Adrenal Gland - 9.02 0.000
3 CYP11B1 cytochrome P450, family 11, subfamily B, polypeptide 1 Adrenal Gland - 8.90 0.000
4 CYP17A1 cytochrome P450, family 17, subfamily A, polypeptide 1 Adrenal Gland - 8.90 0.000
5 ELAVL4 ELAV like neuron-specific RNA binding protein 4 Adrenal Gland + 8.22 0.000
6 SULT2A1 sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 Adrenal Gland - 8.16 0.000
7 HAND2 heart and neural crest derivatives expressed 2 Adrenal Gland + 8.05 0.000
8 STMN2 stathmin 2 Adrenal Gland + 7.76 0.000
9 PHOX2B paired-like homeobox 2b Adrenal Gland + 7.74 0.000
10 ISL1 ISL LIM homeobox 1 Adrenal Gland + 7.46 0.000
11 CYP21A2 cytochrome P450, family 21, subfamily A, polypeptide 2 Adrenal Gland - 7.45 0.000
12 MGST1 microsomal glutathione S-transferase 1 Adrenal Gland - 7.39 0.000
13 TUBB2B tubulin, beta 2B class IIb Adrenal Gland + 7.37 0.000
14 NPY neuropeptide Y Adrenal Gland + 7.34 0.000
15 GSTA1 glutathione S-transferase alpha 1 Adrenal Gland - 7.21 0.000
16 RTN1 reticulon 1 Adrenal Gland + 7.18 0.000
17 ADGRV1 adhesion G protein-coupled receptor V1 Adrenal Gland - 7.16 0.000
18 SCG2 secretogranin II Adrenal Gland + 7.15 0.000
19 DCX doublecortin Adrenal Gland + 7.06 0.000
20 NRK Nik related kinase Adrenal Gland - 7.01 0.000
21 MAB21L1 mab-21-like 1 (C. elegans) Adrenal Gland + 7.01 0.000
22 MRAP melanocortin 2 receptor accessory protein Adrenal Gland - 7.01 0.000
23 MGARP mitochondria-localized glutamic acid-rich protein Adrenal Gland - 6.97 0.000
24 SLC38A1 solute carrier family 38, member 1 Adrenal Gland + 6.95 0.000
25 RIMBP2 RIMS binding protein 2 Adrenal Gland + 6.84 0.000
26 CD24 CD24 molecule Adrenal Gland + 6.82 0.000
27 GNRHR gonadotropin-releasing hormone receptor Adrenal Gland - 6.80 0.000
28 LDLR low density lipoprotein receptor Adrenal Gland - 6.79 0.000
29 FDX1 ferredoxin 1 Adrenal Gland - 6.79 0.000
30 HMP19 HMP19 protein Adrenal Gland + 6.78 0.000
31 CPB1 carboxypeptidase B1 (tissue) Adrenal Gland - 6.76 0.000
32 CRMP1 collapsin response mediator protein 1 Adrenal Gland + 6.70 0.000
33 SOX11 SRY (sex determining region Y)-box 11 Adrenal Gland + 6.65 0.000
34 SYT1 synaptotagmin I Adrenal Gland + 6.61 0.000
35 GAP43 growth associated protein 43 Adrenal Gland + 6.61 0.000
36 TFAP2B transcription factor AP-2 beta (activating enhancer binding protein 2 beta) Adrenal Gland + 6.59 0.000
37 SCN3A sodium channel, voltage gated, type III alpha subunit Adrenal Gland + 6.57 0.000
38 KRT1 keratin 1, type II Blood - 6.56 0.000
39 CELF4 CUGBP, Elav-like family member 4 Adrenal Gland + 6.53 0.000
40 CHGA chromogranin A Adrenal Gland + 6.45 0.000
41 ELAVL2 ELAV like neuron-specific RNA binding protein 2 Adrenal Gland + 6.41 0.000
42 SCARB1 scavenger receptor class B, member 1 Adrenal Gland - 6.33 0.000
43 IGFBPL1 insulin-like growth factor binding protein-like 1 Adrenal Gland + 6.17 0.000
44 INA internexin neuronal intermediate filament protein, alpha Adrenal Gland + 6.16 0.000
45 SNAP91 synaptosomal-associated protein, 91kDa Adrenal Gland + 6.16 0.000
46 CHRNA3 cholinergic receptor, nicotinic, alpha 3 (neuronal) Adrenal Gland + 6.16 0.000
47 PAK3 p21 protein (Cdc42/Rac)-activated kinase 3 Adrenal Gland + 6.15 0.000
48 STMN4 stathmin-like 4 Adrenal Gland + 6.11 0.000
49 SIGLEC11 sialic acid binding Ig-like lectin 11 Adrenal Gland - 6.05 0.000
50 PDZK1IP1 PDZK1 interacting protein 1 Blood - 6.03 0.000
Search GEO for disease gene expression data for Neuroblastoma.

Pathways for Neuroblastoma

Pathways related to Neuroblastoma according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

GO Terms for Neuroblastoma

Sources for Neuroblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....